Demonstration of a specific receptor for human C5a anaphylatoxin on murine macrophages by unknown
DEMONSTRATION  OF  A  SPECIFIC  RECEPTOR  FOR 
HUMAN  C5a  ANAPHYLATOXIN  ON  MURINE  MACROPHAGES* 
BY  DENNIS  E.  CHENOWETH,:I: MICHAEL G.  GOODMAN,§ AND 
WILLIAM O.  WEIGLE 
From the Department of Pathology, University of California at San Diego, LaJolla, California 92093; and 
the Department of Immunopathology, Scripps Clinic and Research Foundation, La Jolla,  California 92037 
Human  C5a  anaphylatoxin  is  a  74  residue  glycopolypeptide cleaved  from  the 
amino terminus of the fifth component of human complement (C5)  during comple- 
ment  activation  (1).  The  C5a  fragment serves  as  a  potent  mediator of the  acute 
inflammatory response.  Its ability to induce mast cell histamine release, enhanced 
vascular permeability, and contraction of smooth muscle account for its spasmogen- 
icity (2-4).  More importantly, human C5a is the most potent complement-derived 
effector of human  neutrophil  function yet  described.  In  vitro,  C5a  is  capable  of 
stimulating neutrophil  chemotaxis,  inducing exocytosis of lysosomal granular  en- 
zymes, enhancing formation of toxic oxygen species,  and promoting enhanced neutro- 
phil adherence and/or autoaggregation (5-9). 
These  neutrophil  responses  ensue  when  C5a  binds  to  specific  receptors  on  the 
neutrophil surface (10). These cells bear ~200,000 C5a receptors, which are charac- 
terized by an apparent Ka of 1-3 nM. Recent investigations have demonstrated that 
neutrophil-bound radioiodinated C5a (l~SI-C5a) is readily degraded to small peptides 
and/or amino acids and is eventually released from the cell. Still other studies suggest 
that proteolytic degradation of C5a occurs only after cellular internalization of the 
ligand (tl, 12). 1 
When C5a is formed in serum or plasma, it is rapidly and irreversibly converted to 
its des Arg-74 derivative  (C5ades~)2  by serum carboxypeptidase N  (E.C.  3.4.17.3) 
(13).  Although human C5adesArg is nearly devoid of spasmogenic activity, it retains 
the ability to stimulate neutrophil responses such as chemotaxis and degranulation 
(6,  7).  Additionally, human C5ad~,~g is capable of binding to the neutrophil C5a 
receptor but with a 50- to 100-fold lower affinity than C5a (6,  10). 
In addition to their neutrophil-related biological activities, C5a and/or C5ade, Arg 
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have  also  been  demonstrated  to  promote  a  variety  of monocyte  and  macrophage 
responses, including enhancement  of migration or chemotaxis  (14-16),  induction of 
lysosomal enzyme secretion (17), and polarization (18). We assume that these cellular 
responses, like those of the neutrophil, result from binding of C5a to specific cellular 
receptors. To confirm this hypothesis, we have characterized the binding interactions 
of radiolabeled human  C5a  with  both  adherent  cells isolated  from  the  peritoneal 
cavity of C3H/HeJ  mice and the murine macrophage cell line designated P388D1. 
Materials  and  Methods 
Preparation of Human CSa and CSa Derivatives.  Human  C5a anaphylatoxin was purified to 
homogeneity from zymosan-activated human serum containing 1 M  e-aminocaproic acid by 
the methods of Fernandez and Hugli (19).  The naturally occurring derivative C5aa~,~, was 
isolated from zymosan-activated human serum in the absence of the carboxypeptidase inhibitor 
(1).  An additional C5a  derivative, termed C5a-(1-69), which consists of the  N-terminal 69 
residues of C5a,  was  prepared  by carboxypeptidase Y  digestion of C5aa~ ~u, as  previously 
described (10). 
Human C5a was radiolabeled with Na 125I (Amersham Corp., Arlington Heights, IL) by a 
solid  phase  lactoperoxidase-glucose oxidase  method  (Enzymobead;  Bio-Rad  Laboratories, 
Richmond,  CA)  using  conditions recommended  by  the  manufacturer  (Bio-Rad  Technical 
Bulletin  1060).  Free 1251 and  damaged radiolabeled C5a were separated from  antigenically 
reactive 12SI-C5a by immunoaffinity chromatography on a  1.0-ml column of rabbit anti-C5a 
IgG-Sepharose 4B. Native 125I-C5a  was eluted with 0.2 M glycine-HC1, pH 2.3, and immediately 
neutralized with 1 M  K2HPO4. The specific activity of such preparations was typically 20-40 
/zCi//zg.  Radiolabeled C5a was judged to have retained its native character by the fact that it 
was  >90%  bound  by an  excess of rabbit  anti-human  C5a  immunoglobulin  in  solid phase 
radioimmunoassays (20) and >85% bound by human neutrophils. 
Mice.  Male mice (C3H/St), 8-12 wk of age, were obtained from the mouse breeding colony 
at Scripps Clinic and Research Foundation. Mice were maintained on Wayne Lab-Blox F6 
pellets (Allied Mills, Inc., Chicago, IL) and chlorinated water acidified with HCI to a pH of 3.0 
(21). 
Cell Isolation and Culture.  Resident peritoneal cells were obtained by peritoneal lavage with 
3.0 ml of a sterile balanced salt solution (BSS)  supplemented with  100 U  of penicillin G/ml, 
100 #g of streptomycin/ml, and 0.5 U  (USP) of sodium heparin/ml. Thioglycollate-induced 
peritoneal cells were similarly obtained 6  d  after intraperitoneal injection of thioglycollate. 
Before use, all peritoneal cells were irradiated with  1,000  rad from a  Gamma cell 40 small 
animal irradiator (Atomic Energy of Canada Ltd., Ottawa, Canada). This irradiator uses a 
cesium  137 source emitting a  central dose-rate of 100 rad/min. Differential cell counts were 
performed  on  each  cell  preparation  before performing  125I-C5a binding assays.  Typically, 
10-30% of resident peritoneal cells were esterase positive, whereas 90-95% of the thioglycollate- 
induced cells were  esterase positive. The  number  of peritoneal cells used  was  adjusted for 
percent cells of monocytoid histology. Cells of this morphological type were radiation-resistant, 
esterase-positive, adherent antigen-presenting cells. For these reasons they will be referred to as 
"maerophages." 
Murine spleen cell suspensions were prepared as previously described (22). These cells were 
depleted of adherent cells by passage over columns of Sephadex G-10 (23).  The lymphocyte 
population recovered from this procedure typically contained <0.12% esterase-positive cells. 
In selected experiments, murine resident peritoneal cells were depleted of Ia-positive cells by 
treatment  with  monoclonal anti-Ia  K antibodies and  complement.  Monoclonal anti-Ia  K was 
obtained as a culture supernatant from hybridoma 10-2.16 developed in the laboratory of Dr. 
L. A. Herzenberg at Stanford University. This antibody is of the 72b subclass. It reacts with Ia 
specificities  of the r, f, and s haplotype in addition to Ia  K (24). Treatment with this supernatant 
followed by addition of guinea pig complement (Colorado Serum Co., Denver, GO) typically 
killed ~ 18% of resident peritoneal ceils from C3H/St mice. 
The cell lines P388 and P388D1  were kindly provided by the Salk Institute for Biological 
Studies, La Jolla, CA. P388 cells were cultured in Dulbecco's minimum essential medium (high 70  MACROPHAGE  C5a  RECEPTOR 
glucose) supplemented with 50 gM 2-mercaptoethanol, 20 mM Hepes, and 10% heat-inactivated 
fetal calf serum (FCS). P388D1 cells were cultured in RPMI 1640 supplemented with 5% heat- 
inactivated  FCS.  Additionally,  both  types  of media  were  supplemented  with  glutamine, 
nonessential  amino acids, and  antibiotics as described for lymphocyte culture  (22).  Human 
peripheral blood neutrophils were prepared from the heparin-anticoagulated venous blood of 
healthy male volunteers according to standard methods (25). 
l~I-C5a Cell Binding Assays.  Cellular binding of a25I-C5a was assessed by previously published 
methods  (10).  Briefly,  125I-C5a was diluted  to an appropriate  concentration  (0.3-60  nM)  in 
Hanks' balanced salt solution containing 0.5% gelatin (HBSS-G) (Microbiological Associates  , 
Walkersville,  MD)  and incubated with test  cells suspended in HBSS-G. Incubation volumes 
were routinely 100 #1, and binding reactions were carried out in 1.5-ml conical polypropylene 
mierofuge tubes (Cole Scientific,  Calabasas, CA). To terminate the binding reaction, cells were 
rapidly pelleted by centrifugation at 11,000 g in a Beckman Microfuge B (Beckman Instruments, 
Inc., Palo Alto, CA) for 30 s. To determine  the amount of cell-bound 125I-C5a, one-half the 
supernatant solution plus tile material remaining in the microfuge tube (residual  supernatant 
and  cell  pellet)  was  counted  as  a  paired  sample  in  a  Packard  Autogamma  Spectrometer 
(Packard Instrument Co., Downers Grove, IL) with 70% efficiency.  The amount of cell-bound 
125I-C5a was then calculated from the formula given previously (10). Nonspecific binding of 
x2~I-C5a to polypropylene tubes was <1% when assays were performed in this manner. 
Identification of l~I-C5a Degradation Products.  Molecular sieve ehromatography was utilized to 
identify  125I-C5a degradation  products  released  by  murine  macrophages  upon  prolonged 
incubation at 37°C. For these experiments, peritoneal cells from C3H/HeJ mice (1 ×  107/ml 
in HBSS-G) were incubated with  1 nM 125I-C5a for 20 min at 37°C to permit ligand binding. 
After removal of unbound 12~I-C5a by washing, the cells were resuspended  in  HBSS-G and 
incubated for an additional 2 h at 37°C. Cells were then pelleted by centrifugation, and  100 
gl of the incubation supernatant was removed and chromatographed on a 0.7 ×  30-cm column 
of Bio Gel P-100 (100-200 mesh; Bio-Rad Laboratories). The column was eluted at a flow rate 
of 4.65  ml/h  with  phosphate-buffered  saline,  pH  7.4, and  0.3-ml  fractions were  collected. 
Radioactive  content  of individual  fractions was  assessed  by counting gamma emissions  as 
above. 
Results 
Time  Course and  Temperature Dependence of 12SI-C5a Binding.  The  time  course  of 
125I-labeled human C5a binding to resident  murine peritoneal  macrophages at  both 
4°C and 37°C is shown in Fig.  1. Cellular uptake of the ligand was equally rapid at 
both  temperatures.  At  4°C,  binding  was  maximal  after  45  min,  and  steady-state 
binding  was  demonstrable  with  incubation  for up  to  120  min.  When  binding  was 
carried out at 37°C, maximal cellular uptake of 125I-C5a was observed after 20 min 
incubation. With more prolonged incubation at this temperature,  the amount of cell- 
bound  radioisotope  steadily  decreased,  being  barely  detectable  after  120  min  of 
incubation. This type of kinetic profile, i.e., ligand uptake followed by cellular release 
of radioisotope,  has  been  consistently  observed  when  a25I-C5a  is  incubated  with 
neutrophils  at  37°C  (11,  12)  or when  target  cells  bind  and  subsequently  degrade 
bioaetive polypeptides  (reviewed in 26). 
To  determine  if murine  macrophages  degrade  cell-associated  125I-C5a, cells  that 
had been incubated with lzsI-C5a for 20 min at 37°C were washed and incubated in 
the  absence  of C5a  for an  additional  2  h  at  37°C.  When  supernatants  from these 
cultures  were subjected  to gel  filtration  chromatography on Bio  Gel  P-100  (Fig.  2) 
only ~ 15% of the released radioisotope eluted as intact a25I-C5a. The vast majority of 
the  radioactive  material  eluted  between  11  and  13.5  ml,  a  position  whose  elution 
volume  was  consistent  with  that  of mono-iodotyrosine  or  small  peptides.  Further 
analysis of this  low molecular weight  fraction demonstrated  that  it  did not bind  to CHENOWETH,  GOODMAN,  AND  WEIGLE  71 
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Fie.  1.  Time  course  of binding  of  125I-labeled  human  C5a  to  C3H/HeJ  resident  peritoneal 
macrophages. Cells were suspended at a  density of 5 ×  I0  s macrophages (esterase-positive cells)/ml 
in  HBSS-G  and  incubated  a  final  concentration  of 0.3  nM  125I-C5a  at  4°C  (0)  or  37°C  (©). 
Duplicate  100-/tl  aliquots were removed at the indicated times, and the amount of cell-associated 
radiolabel determined as described in Materials and Methods. Results of duplicate determinations 
in a single experiment are shown. Three additional experiments gave comparable results. 
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Fzo.  2.  Bio Gel  P-I00 column chromatography of radiolabel  released from murine (C3H/HeJ) 
resident peritoneal macrophages. Cells (1 ×  107/ml in HBSS-G) were incubated with 1 nM 125I-C5a 
for 20 min at  37°C, washed to remove unbound ligand, resuspended in HBSS-G at  a  density of 
1 X  107/ml, and incubated for an additional 2 h at 37°C. Cells were pelleted by centrifugation, and 
a  100-#1 aliquot of the incubation supernatant was chromatographed on a  0.7 ×  30-cm column of 
P-100 resin. Two separate experiments gave identical results. 
either  human  neutrophils  or  to  freshly-prepared  murine  peritoneal  macrophages. 
Additionally, it was not bound by an excess of rabbit anti-human C5a immunoglob- 
ulin. 
Concentration  Dependence of z~I-labeled Human C5a  Binding to  Murine Macrophages. 
Incubation of murine resident peritoneal macrophages with varying concentrations of 
125I-C5a for 20 min at  37°C  demonstrated a  saturable binding interaction, with a 
nonspeeific binding component at elevated ligand concentrations (Fig. 3). A Scatchard 
plot of these data  (Fig.  4)  suggested the existence of a  single class of high affinity 
cellular receptors  as well as  low affinity (nonspecific)  binding interactions.  Linear 
regression analysis (correlation coefficient =  0.998)  of the high affinity binding data 72  MACROPHAGE  C5a  RECEPTOR 
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FIG.  3.  Concentration  dependence  of  l~I-labeled  human  C5a  binding  to  C3H/HeJ  resident 
peritoneal macrophages. Cells were suspended at a density of 1 ×  107 macrophages/ml  in HBSS-G 
and incubated with varying concentrations of ~2SI-C5a for 20 min at 37°C. Cell-bound ~25I-C5a was 
determined  in  triplicate  as  described.  Each  data  point  represents  the  mean  value  of triplicate 
determinations in three separate experiments. Nonspecific binding has not been subtracted from the 
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FIG. 4.  Scatchard plot of data presented in Fig. 3, showing binding of z25I-labeled  human C5a to 
murine peritoneal macrophages, 
provided an estimate of the apparent Kd of the murine peritoneal macrophage C5a 
receptor as 3 nM. The average number of C5a receptors per cell was estimated  to be 
2 ×  105. 
Ligand Specificity of the Macrophage C5a Receptor.  Incubation of murine  peritoneal 
macrophages  with a  fixed amount of 12SI-C5a and increasing amounts of unlabeled 
C5a  resulted  in  progressive  diminution  of  z25I-C5a  binding  (Fig.  5).  The  ligand 
specificity  of the  murine  macrophage  C5a  receptor  was  further  confirmed  by  the 
observation that the unlabeled C5a derivatives C5aaes A~g and C5a-(1-69) also proved 
capable of inhibiting cellular binding of 125I-C5a. These two ligands, which display 
lower affinity binding than C5a, produced half maximal inhibition of C5a binding at 
approximate  concentrations  of  1.6  ×  10  -6  M  and  2.4  ×  10 -5  M,  respectively. 
Qualitatively  similar  results  have  been  obtained  with  the  human  neutrophil  C5a 
receptor (6, 27). The chemotactic oligopeptide N-formyl-methionyl-leucyl-phenylala- 
nine  (N-f-MLF),  which  also  binds  specifically  to  macrophages  (28,  29),  did  not CHENOWETH, GOODMAN, AND WEIGLE  73 
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Fzo.  5.  Ligand specificity of 125I-labeled human C5a binding to C3H/HeJ  resident peritoneal 
macrophages.  Macrophages  (2.5 ×  10S/ml in HBSS-G) were simultaneously incubated for 20 min 
at 37°C with radiolabeled C5a (1 nM) and varied amounts of unlabeled C5a (O), C5ad~A~ (11), 
C5a-(1-69) (A), or N-F-MLF (O). The amount of lzSI-C5a bound to cells in the absence or presence 
of competing ligand was determined as described.  Each data point represents  the mean value of 
duplicate determinations in two experiments. 
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Fie.  6.  Cellular specificity of 125I-labeled human C5a binding to various  types of murine ceils. 
Resident peritoneal macrophages  (0), thioglycollate-elicited  peritoneal maerophages  (O), or splenic 
lymphocytes  prepared  by  passage  through  Sephadex  G-10  (11) were  incubated with  varying 
concentrations of 125I-C5a for 20 min at 37°C. Each data point represents the mean value obtained 
from triplicate determinations in a single experiment. Two additional experiments gave comparable 
results. Nonspecific binding,  determined by computer-assisted graphical analysis (31), was subtracted 
from each curve. 
displace z25I-C5a from murine macrophages even though it was present in a  10  s molar 
excess, thus indicating that C5a receptors and oligopeptide receptors exist as separate 
entities on the macrophage surface. Similar findings have been obtained with neutro- 
phils (30). 
Cellular Specificity of the C5a Receptor.  The cellular specificity of z2SI-labeled human 
C5a binding was  analyzed by determining the concentration-dependent binding of 
125I-C5a  to  a  variety  of cells.  As  shown  in  Fig.  6,  saturable  binding  of  C5a  was 
demonstrable  with  resident  peritoneal  macrophages  as  well  as  cells  elicited  by the 
prior  administration  of  thioglycollate.  Both  types  of cells  exhibited  half-maximal 74  MACROPHAGE C5a  RECEPTOR 
TABLE I 
Binding of leZl-labeled Human C5a to Macrophages 
Appar-  Receptor 
Cell type  Origin  ent Kd*  number  S 
nM 
Resident peritoneal macrophage  Murine (C3H/HeJ)  2-3  200,000 
Thioglycollate-induced peritoneal macrophage  Murine (C3H/HeJ)  2-3  40,000-50,000 
.Splenic lymphocytes  Murine (C3H/HeJ)  0§ 
P388D1  Murine  2-3  80,000-100,000 
P388  Murine  0§ 
* Kd estimated from half-maximal uptake of 125I-C5a. 
$ Receptor number estimated from saturable portions of 125I-C5a uptake curves. 
§ No detectable specific binding of 12~I-C5a. 
uptake of 125I-C5a at a  concentration of 20 ng/ml  (2.5  nM), implying that the C5a 
receptors  of each  cell  type  exhibited  the  same  apparent  Ka.  On  the  other  hand, 
resident macrophages displayed ~2  ×  105 receptors/cell, whereas the thioglycollate- 
induced  macrophages  possessed  only  4-5  ×  104  C5a  receptors  per  cell.  Splenic 
lymphocytes, rendered free of adherent cells by passage through Sephadex G-10, did 
not bind 125I-C5a. Thus, the C5a receptor is expressed by macrophages, but  is not 
found in significant numbers on murine splenic lymphocytes. 
Additional  studies  of this  type  have  also  been  conducted  to  determine  if C5a 
receptors exist on murine macrophage cell lines. The results of these investigations are 
summarized in Table I. Our findings indicate that the cell line P388D1, but not its 
parent P388, expressed C5a receptors. The apparent Ka of the C5a receptor expressed 
by P388D1 was 2 nM, and 8-10 ×  104 C5a binding sites were detectable on each cell. 
We  have  also  assessed  the  binding  of t25I-C5a  to  unseparated  and  Ia-depleted 
murine  cells.  To accomplish  this,  Ia-positive cells  were  removed  from  the  normal 
peritoneal macrophage population by lysis with specific anti-Ia antiserum and com- 
plement. Evaluation of the binding of 1 nM 12gI-C5a for 20 min at 37°C by normal 
and Ia-depleted cells demonstrated that the normal mixed cell population bound 36.3 
+  1.8 (mean -- SD) fmol of 125I-C5a, whereas the macrophage population depleted of 
Ia-positive cells bound 47.6 ±  1.2 (mean -t- SD) fmol of z2~I-C5a. This difference was 
judged to be statistically significant (P <  0.001). 
Discussion 
Our  current  investigations  clearly  demonstrate  that  murine  macrophages,  like 
human peripheral blood neutrophils (10), possess a  specific receptor for the comple- 
ment-derived C5a anaphylatoxin. The characteristics of the murine macrophage C5a 
receptor are quantitatively similar to those of the human  neutrophil  (10), i.e., the 
apparent Ka is estimated to be 2-3 nM, and each cell bears ~200,000 C5a receptors. 
Radiolabeled human C5a binds rapidly to macrophages obtained from the peritoneal 
cavity of C3H mice. The rate of association of the ligand with these cells appears to 
be equally rapid  whether binding  takes  place at  4°C  or 37°C,  implying receptor- 
mediated uptake of the biologically active factor. When incubations are conducted 
entirely at 4°C, steady-state binding is obtained. In contrast, when binding interac- 
tions take place at 37°C, uptake and time-dependent release of radiolabel is observed, 
suggesting  that  a  temperature-dependent  process(es), such  as  internalization,  is  re- CHENOWETH, GOODMAN, AND WEIGLE  75 
sponsible for these phenomena (12). Therefore, murine peritoneal macrophages appear 
to behave like human neutrophils, being capable of degrading cell-bound 125I-C5a. 
Although we have not specifically attempted to prove that  murine macrophages 
internalize 125I-C5a like human neutrophils,  1 we have clearly demonstrated that the 
macrophage is capable of degrading C5a to its constituent amino acids and/or small 
peptides. Supernatants recovered from cells incubated with 125I-C5a for 2 h  at 37°C 
were chromatographically resolved on a  molecular sieve resin and shown to consist 
predominantly of low molecular weight radiolabeled fragments. The fact that these 
low  molecular  weight  species  were  not  bound  by  either  freshly-prepared  human 
neutrophils, murine macrophages, or anti-C5a immunoglobulin indicated that  they 
were neither biologically nor antigenically reactive. Thus, macrophages, like neutro- 
phils, are able to degrade and inactivate cell-bound C5a. Based on our own observa- 
tions with neutrophils  1 and the study of polypeptide hormones conducted by many 
other  investigators  (26),  it  is  likely  that  macrophage  internalization  of  125I-C5a 
precedes the degradative-inactivation process(es). 
Resident macrophages isolated from the peritoneal cavity of  C3H mice demonstrate 
a single class of high affinity C5a receptors. Scatchard analysis of t25I-C5a concentra- 
tion-dependent binding data indicates that these receptors display an average Ka of 
3  nM,  and  that  there are  ~2  ×  105 receptors on each cell.  These values correlate 
closely with those observed for human neutrophils (10). Some low affÉnity or nonspe- 
cific binding interactions are also demonstrated by this type of analysis. The fact that 
a  100-fold  molar  excess  of unlabeled  C5a  completely blocks  binding  of 125I-C5a 
suggests that these low affinity interactions may represent a second population of low 
affinity receptors rather than simply nonspecific binding. 
The  C5a  receptors  of murine  macrophages,  like  their  neutrophil  counterparts, 
exhibit  a  high  degree of ligand  specificity  (6,  10). Unlabeled  human  C5a  and  its 
derivatives C5ades ~g and C5a-(1-69) are all capable of inhibiting 125I-C5a binding to 
the  macrophage  receptor.  The  relative  affinities  of  each  unlabeled  ligand,  i.e., 
C5a>C5ade~g>C5a-(1-69),  are  comparable  to  those  demonstrated  with  human 
neutrophils (6,  10). These findings imply that the macrophage C5a receptor may be 
structurally analogous to the human neutrophil C5a receptor. If this is true, then the 
macrophage C5a receptor may consist of both a ligand binding domain that interacts 
with the N-terminal region of C5a and an activation binding domain that specifically 
interacts with the C-terminal portion of C5a (6). 
The macrophage  C5a  receptor is  found not  only on  murine  resident  peritoneal 
macrophages, but is also demonstrable on thioglycollate-induced peritoneal cells and 
cultured cell lines. In all instances, the apparent Kd of the receptor is nearly identical, 
being  I-3 nM. Adherent cells from different sources appear to differ predominantly 
with regard to the number of receptors expressed. For example, resident peritoneal 
macrophages have four to five times as many receptors as their thioglycollate-induced 
counterparts  and  approximately twice as  many receptors as  the  P388D~  cell  line. 
Interestingly, the cell  line  P388,  which  is  the parent  of P388Da,  fails  to express a 
detectable number of C5a receptors. The fact that  C5a  receptor density may vary 
widely, whereas the apparent Ka remains constant, is substantiated by the observation 
that  human  alveolar macrophages,  guinea  pig  alveolar macrophages,  and  human 
peripheral blood monocytes display C5a receptors whose apparent Kd values are 1-3 
nM.  However, each of these cell types express differing numbers  of receptors, i.e., 76  MACROPHAGE  C5a  RECEPTOR 
human alveolar macrophages, ~3  ×  105; guinea pig alveolar macrophages, ~0.5  × 
105; and human monocytes, ~ 1 ×  105 (unpublished observations). 
We have observed that  lysis of Ia-positive cells with specific anti-Ia antisera and 
complement actually increases subsequent binding of 125I-C5a to the viable peritoneal 
cells remaining in culture. The magnitude of the enhancement of 12~I-C5a specific 
uptake is consistent with the fact that such lytic procedures removed the  10-20% of 
Ia-positive cells, which would be normally expected in the resident peritoneal mac- 
rophage population, and implies that Ia-negative cells are largely responsible for the 
observed binding of C5a. This conclusion is substantiated by the finding that the Ia- 
negative cell line P388D1 also binds 125I-C5a. 
Although other investigators have demonstrated that C5a or a similar polypeptide 
in activated serum is capable of promoting macrophage cellular responses (14-18), we 
have chosen  to  focus on  a  new  biological  activity ascribable  to C5a.  As  we  have 
demonstrated,  C5a  promotes macrophage-dependent enhancement  of the  immune 
response.  3 The close correspondence between the observed dose-response profile for 
this  phenomenon  and  that  of 125I-C5a binding  to  macrophages  implies  that  the 
binding  of C5a  to  its  macrophage  receptor eventuates  in  a  significant  biological 
response and further confirms the specific nature of the macrophage C5a receptor. 
Summary 
Human  C5a  anaphylatoxin  is  known  to  be  a  potent  mediator  of  the  acute 
inflammatory response. It serves to trigger a wide variety of neutrophil responses after 
binding to a specific cellular receptor. We have now demonstrated that this bioactive 
glycopolypeptide is  also  bound  to  a  specific  receptor  found  on  murine  resident 
peritoneal macrophages, thioglycollate-induced exudate macrophages, and the murine 
cell line P388Dx. The apparent Kd of the C5a receptor for each cell type is ~2 nM, 
but each cell expresses a  differing number of C5a receptors. Resident macrophages 
appear to have an average of 2 ×  105 binding sites per cell, whereas thioglycollate- 
induced cells have only 4-5  ×  104 binding sites.  The continuous cell line P388D1 is 
intermediate between these two cell types, exhibiting 8-10 ×  104 C5a receptors per 
cell. Neither murine lymphocytes nor the parent cell line P388 displays a measurable 
number of C5a receptors. Macrophage receptor-C5a binding interactions are followed 
by cellular uptake and degradation of a25I-C5a, much as is observed with neutrophils. 
As  demonstrated  in  another  paper,  binding  of C5a  to  macrophages  results  in 
augmentation of the primary humoral immune response as well as enhancement of 
mixed lymphocyte reactions.  3 These observations suggest that C5a should not only be 
considered as an acute inflammatory mediator but as an immunopotentiating mod- 
ulator as  well,  thus  serving as  a  critical  link  between complement  activation  and 
subsequent immune responses. 
Received  for publication 21 September 1981. 
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